Clinical Trials Browser

Phase 1/2 × OTHER × Interleukin-2 × Clear all

NCT06598371 2026-05-20

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Select Advanced Solid Tumors

NCT07591649 2026-05-19

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06158828 2026-05-05

ABCD-NK

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06961357 2026-03-31

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Phase 1/2 Recruiting

Uveal Melanoma, Melanoma

NCT04347616 2026-03-16

NK4AML

Phase 1/2 Terminated

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT07389239 2026-02-20

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

Phase 1/2 Not yet recruiting

Ovarian Neoplasms

NCT06237881 2026-02-18

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Phase 1/2 Active not recruiting

DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

NCT07410494 2026-02-18

SELECT-CAR-NK

Phase 1/2 Recruiting

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Phase 1/2 Recruiting

BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT05821686 2025-02-12

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Phase 1/2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06532799 2024-11-12

BAH250

Phase 1/2 Recruiting

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06532812 2024-11-12

BAH249

Phase 1/2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06530303 2024-11-05

BAH248

Phase 1/2 Recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06640582 2024-11-05

BAH2472

Phase 1/2 Recruiting

Brain Neoplasms, Glioblastoma, Glioma, Meningioma

NCT06538012 2024-10-15

BAH2472

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03658785 2024-08-13

Immunotherapy for the Treatment of Advanced Solid Tumor

Phase 1/2 Recruiting

Neoplasm Metastasis, Recurrence

NCT03098355 2024-03-18

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT01898793 2024-01-17

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 1/2 Terminated

89 enrolled 17 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04729543 2023-12-04

MC2TCR

Phase 1/2 Recruiting

DermatologicHead & Neck

Uveal Melanoma, Head and Neck Neoplasms, Melanoma

NCT05981001 2023-08-08

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT05981014 2023-08-08

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT03287674 2023-03-01

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Phase 1/2 Completed

7 enrolled 10 charts

Ovarian Neoplasms

NCT02414945 2023-01-10

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

Phase 1/2 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT00945269 2022-11-15

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Phase 1/2 Terminated

Melanoma

NCT03374839 2022-05-06

Nivo-TIL

Phase 1/2 Unknown

Melanoma

NCT02989714 2021-07-13

Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer

Phase 1/2 Completed

13 enrolled 11 charts

Carcinoma, Renal Cell

NCT01701479 2020-07-14

LTI

Phase 1/2 Unknown

Neuroblastoma

NCT02354690 2020-03-23

Vemurafenib and TIL Therapy for Metastatic Melanoma

Phase 1/2 Completed

13 enrolled 12 charts

Melanoma

NCT02379195 2020-01-22

Peginterferon and TIL Therapy for Metastatic Melanoma

Phase 1/2 Completed

12 enrolled 10 charts

Melanoma

NCT01550367 2020-01-02

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

Phase 1/2 Completed

30 enrolled 20 charts

Carcinoma, Renal Cell

NCT03111901 2019-07-12

UVA-AM-002

Phase 1/2 Withdrawn

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT01191034 2019-03-12

Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma

Phase 1/2 Terminated

Melanoma

NCT02173093 2019-01-29

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

Phase 1/2 Unknown

Neuroblastoma

NCT03297463 2018-08-01

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Phase 1/2 Withdrawn

CNSDermatologic

Brain Neoplasms, Melanoma

NCT00303667 2017-12-28

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Phase 1/2 Completed

50 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00625729 2017-12-28

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Phase 1/2 Terminated

6 enrolled 10 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT03171220 2017-06-06

NRT-01

Phase 1/2 Unknown

Other solid neoplasm

Advanced Malignant Solid Tumor

NCT03044743 2017-05-02

PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies

Phase 1/2 Unknown

GastrointestinalHead & NeckLymphoid

Nasopharyngeal Carcinoma, Hodgkin Disease, Stomach Neoplasms, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00871481 2017-04-19

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Phase 1/2 Completed

Melanoma

NCT00052520 2017-03-29

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

Phase 1/2 Completed

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00052598 2017-02-15

Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant

Phase 1/2 Terminated

Other hematologic neoplasm

Congenital Abnormalities, Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

NCT00553306 2017-02-15

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

Phase 1/2 Completed

Melanoma

NCT01278940 2016-08-15

Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma

Phase 1/2 Completed

Melanoma

NCT02315118 2016-06-22

Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00937625 2015-08-18

T-cell Based Immunotherapy for of Melanoma

Phase 1/2 Completed

Melanoma

NCT01743157 2013-08-29

BBI

Phase 1/2 Completed

Melanoma

NCT01409187 2012-01-26

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma

Phase 1/2 Withdrawn

Melanoma

NCT00277017 2011-09-27

Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma

Phase 1/2 Completed

Carcinoma, Renal Cell, Neoplasms

NCT00197912 2010-04-26

Dendritic Cell Based Therapy of Malignant Melanoma

Phase 1/2 Completed

Melanoma